Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.46 |
| ▸ | ITGAV | P06756 | 5/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.45 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016455 | 0.89 | HDAC6 (0.43) | HDAC6FDPSPPARAITGB3ITGAV | |
| SCHEMBL6016459 | 0.89 | HDAC6 (0.43) | HDAC6FDPSPPARAITGB3ITGAV | |
| SCHEMBL6811091 | 0.82 | ITGB3 (0.53) | ITGB3ITGAV | |
| SCHEMBL4640793 | 0.80 | ITGB3 (0.47) | ITGB3ITGAV | |
| SCHEMBL4640796 | 0.80 | ITGB3 (0.47) | ITGB3ITGAV | |
| SCHEMBL4641583 | 0.80 | ITGB3 (0.55) | ITGB3ITGAV | |
| SCHEMBL4640279 | 0.80 | ITGB3 (0.48) | ITGB3ITGAV | |
| SCHEMBL4640271 | 0.80 | ITGB3 (0.48) | ITGB3ITGAV | |
| SCHEMBL6807080 | 0.79 | ITGB3 (0.40) | PPARAITGB3ITGAVPPARG | |
| SCHEMBL6804197 | 0.78 | ITGB3 (0.47) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992187-B2 | Process for the preparation of birthonectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20040248907-A1 | Process for the preparation of birthonectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1315728-B1 | PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2004-10-27 | — | — | EP | disclosed |
| EP-1315728-A1 | PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002018384-A1 | PROCESS FOR THE PREPARATION OF VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248907-A1 | Process for the preparation of birthonectin receptor antagonists | NGFR, TNFSF11, NRP1 | HDAC6 2586/4885FDPS 1413/4885PPARA 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.